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Abstract
Objectives This in situ study aimed to determine and compare the chlorhexidine (CHX) retention in the oral cavity after the
application of different CHX pharmaceutical regimens.
Methods Five volunteers used different CHX treatment regimens including mouth rinses, dental spray and toothpaste gel. After the
application of the different CHX regimens, 2-μl samples were taken from saliva and buccal mucosa pellicle as well as the dental
pellicle samples formed on standardized enamel surfaces. Sample collection was conducted at six time points within 12 h. Retention
of CHX was measured using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
Results CHX retention values in the oral mucosa pellicle were significantly higher than those in saliva. CHX remained in the
mucosal pellicle at microgrammes per millilitre levels for 12 h after mouth rinsing, 10 h after spray application and 2 h after using
the toothpaste. CHXwas detected in the dental pellicle for at least 12 h after application of mouth rinsing and spray. Retention of
CHX after mouth rinsing or spray application was significantly higher than the retention after using toothpaste.
Conclusions Oral mucosa was the favourable site for CHX retention. Higher mouth rinse concentration and longer rinsing time
produced a slight increase in CHX retention. CHX spray provided considerable retention values, whereas toothpaste gel delivered
the lowest retention after application. MALDI-TOF was a sensitive method with excellent limits of quantification for CHX
detection.
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Introduction
Chemotherapeutic agents have the potential to inhibit plaque
growth, reduce gingivitis and improve oral health in combi-
nation with mechanical plaque control [1].
Chlorhexidine (CHX), a bicationic bisbiguanide, is consid-
ered the most effective antimicrobial agent for chemical con-
trol of plaque formation and prevention of caries for more than
50 years [2–4]. In 1954, CHX was first introduced in the UK
as a disinfectant and topical antiseptic [5]. CHX exhibits a
wide spectrum of antibacterial activity that targets both
Gram-positive and Gram-negative bacteria as well as yeast,
dermatophytes and some lipophilic viruses [6]. The first clin-
ical study demonstrating the ability of CHX to inhibit the
formation and development of bacterial plaque was published
in 1970 [2]. Since then, CHXhas been delivered in a variety of
formulations and vehicles, such as mouth rinse, spray, tooth-
paste, gel, varnish and slow-release devices. Solutions with
alcohol or alcohol-free 0.2% CHX have been recommended
as a mouth rinse in 10-ml volumes (20 mg dose). CHX solu-
tions with a concentration of 0.12% are also used as a mouth
rinse but in 15-ml volumes (18 mg dose) [7, 8]. Small doses of
approximately 1.5 ml CHX (3 mg dose) delivered from a
spray to tooth surfaces, particularly in physically and mentally
handicapped groups, also showed good anti-biofilm activity
[9–12]. Several systematic reviews concluded that tooth
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brushing with CHX-containing toothpaste is effective in con-
trolling plaque and gingivitis to some degree, especially after
using high concentrations of CHX. However, CHX toothpaste
was not as effective as CHX mouth rinse [13, 14].
After application, CHX binds to many sites in the oral
cavity and is slowly released to provide a sustained antimicro-
bial effect. This CHX considerable substantivity restricts bac-
terial proliferation for at least 24 h [15–18]. Unfortunately,
this positive outcome of CHX is accompanied by side effects
such as brown staining of teeth and restorations, unpleasant
taste and an increase in calculus deposition [19, 20].
Previously, direct ultraviolet spectroscopy was often used
for determining CHX concentrations; however, it is unspecific
for CHX detection because of the distribution by several sali-
vary components [21]. Therefore, techniques based on
radiolabelling with carbon-14 [15] or fluorometric methods
[22] were subsequently used. Due to the higher sensitivity,
14C-labelled CHX could be detected in saliva 24 h after admin-
istration, but this method is ethically inapplicable to humans.
Fluorometric methods were limited to determine CHX in aque-
ous solutions and centrifuged saliva, but did not work in whole
saliva samples. Different approaches of high-performance liq-
uid chromatography (HPLC) have been used for CHX detec-
tion [23–26]. Additionally, solid-phase microextraction
(SPME) was used to monitor free and total concentrations of
CHX in pharmacokinetic investigations [27]. However, HPLC
and SPME methods require generally long analysis times for
multiple extraction and cleaning steps [28].
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) was used to detect
CHX inmicrotome slices of a bacterially contaminatedwound
model treated with CHX [29]. Recently, we were able to de-
termine and compare the CHX retention in samples from dif-
ferent oral locations by using MALDI-TOF [18]. The
MALDI-TOF approach offers several advantages such as high
sample-throughput, accurate mass analysis and identification
and limited sample clean-up steps [30].
The present study aimed to use the aforementioned advan-
tages of the MALDI-TOF technique to evaluate and compare
the retention of CHX in the oral cavity after using different
CHX delivery systems (rinse, spray, toothpaste gel) and treat-
ment regimens, with the aim of discovering additional infor-
mation on the pharmacokinetics and the efficiency of these
different regimens at different oral sites.
Materials and methods
Human subjects
Oral cavity samples were collected for the present experimen-
tal study from five non-smoking volunteer subjects (3 fe-
males, 2 males), aged 24–36 years.
Visual oral examinations were carried out by an experi-
enced dentist. The parameters used for this oral examination
were PSR index (Periodontal Screening and Recording) for
the determination of periodontal diseases [31] and ICDAS
index (International Caries Detection and Assessment
System) for the detection of active dental caries [32]. To avoid
oral diseases that could potentially affect the oral fluid com-
position and play an unintended role in the CHX substantivity,
all recruited subjects had an oral situation of Code 0 in both
indices, PSR and ICDAS. This means that the subjects did not
have any periodontal diseases and/or any evidence of dental
caries. Additional exclusion criteria were conducted in the
present study including the following: pregnancy, nursing
women, antibiotic therapy within the previous three months,
smoking and any systemic disease.
The number of volunteers included in the study was decid-
ed based on previous reports [15, 18, 21–27], where similar or
even less numbers of subjects were included. All the volun-
teers who participated in the present study were chosen from
the laboratory staff according to the aforementioned inclusion
criteria. The subjects gave their informed written consent to
participate in this study. The study protocols and informed
consent were performed under the guidelines of the
Declaration of Helsinki. Oral sample collection protocols
were approved by the medical ethics committee of the
Medical Association of Saarland, Germany (238/03, 2016).
Study design
Experiments were performed over a period of 12 h and began
at 7 am with the selected individual. Extensive oral hygienic
procedure was performed at least 60 min before starting the
experiment. No further oral hygienic procedures were per-
formed until the end of the 12 h period of the experiment.
The volunteers were instructed to take only one main food
meal 5 h after the start of the experiment and they were
allowed to consume different beverages during the time of
the experiment.
The study lasted for about 1 year, starting with the concep-
tion and study design, then samples collection and CHX quan-
tification, ending with data acquisition, statistical analysis and
data interpretation.
Reagents
CHX digluconate solutions with concentrations of 0.2% and
0.12% in 7% ethanol (Saarland University Pharmacy,
Homburg, Germany), Chlorhexamed® Forte 0.2% alcohol-
free spray (GlaxoSmithKline Consumer Healthcare GmbH
& Co. KG, Bühl, Germany), Curasept ADS® 712 gel tooth-
paste with 0.12% CHX digluconate (Curaden Swiss GmbH,
Stutensee, Germany) and GUM® Paroex® dental gel with
0.12% CHX digluconate (Sunstar GmbH, Schönau,
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Germany) were used for the different CHX regimens. Sterile
water (B. Braun, Melsungen AG, Germany), acetonitrile
100% and trifluoroacetic acid 99% (VWR International
GmbH, Darmstadt, Germany), as well as α-cyano-4-
hydroxycinnamic acid (CHCA, Sigma-Aldrich, Steinheim,
Germany), were used for matrix preparation. Disposable plas-
tic spatulas (Ecospatula, Carl Roth GmbH & Co. KG,
Karlsruhe, Germany) were used for scraping the buccal mu-
cosa surface to collect the mucosal pellicle samples. MALDI
384 well stainless steel plates (Sciex, Darmstadt, Germany)
were used as targets.
Chlorhexidine regimens
Ten millilitres of 0.2% or 0.12% CHX digluconate mouth
rinse was used for 30 and 60 s, respectively. Twelve
squirts (one squirt equals 137 μl) of CHX digluconate
spray were directly applied to the teeth (6 squirts at each
jaw) and then rinsed with total squirts (1.644 ml of 0.2%
CHX) for 1 min (the CHX digluconate dose after spray
application was 3.288 mg). One gram of Curasept ADS®
712 gel toothpaste and 1 g of GUM® Paroex® gel tooth-
paste (both containing 1.2 mg of CHX digluconate) were
used for 2-min brushing. The volunteers used the afore-
mentioned CHX formulations (rinses, spray and tooth-
pastes) according to the manufacturer’s instructions and
there was no new treatment regimen investigated in the
present study.
Sample collection
Experimental samples were taken in the present study as fol-
lows: (1) 2 μl of sample was taken from the whole saliva; (2)
2 μl of sample of the buccal mucosa pellicle was taken from
the collected pellicle after scraping the mucosal area with a
plastic spatula; (3) dental pellicle sample was formed on one
round enamel specimen with a standard surface area of 11.35
mm2. Enamel specimens were prepared from the labial sur-
faces of cattle incisor teeth. The specimens were polished by
wet grinding with abrasive papers (up to 4000 grit) and fixed
on an individual palatal splint (Fig. 1) before the exposure to
the oral cavity. For the production of the palatal splint, alginate
impression (Blueprint cremix®, Dentsply DeTrey, Konstanz,
Germany) was made for the upper jaw of each subject to
produce an elastic mould. Using this mould, a hard plaster
model was made. A transparent custom-made acrylic splint
(Thermoforming foils®, Erkodent, Pfalzgrafenweiler,
Germany) covering the palatal area was made on the plaster
model as a carrier of the enamel specimens. In order to better
stabilize the mounted specimens, the splint was provided with
small perforations. The enamel specimens were fixed to the
individual acrylic splint using silicon impression material
(president light body®, Colténe, Altstaetten, Switzerland).
After application of different CHX digluconate regimens,
samples from each subject were taken at six time intervals (2
h, 4 h, 6 h, 8 h, 10 h, and 12 h). After removal from the oral
cavity, samples were individually dissolved in 100 μl CHCA
matrix solutions (10mg/mlα-cyano-4-hydroxycinnamic acid,
70% acetonitrile and 0.07% trifluoroacetic acid) followed by a
further dilution step to adjust CHX concentrations to the
MALDI-TOF method. From each diluted sample, 5 spots of
0.5 μl each were pipetted via the dried-droplet method onto a
polished MALDI target plate and allowed to dry [18].
Calibration curve of chlorhexidine
A working solution of 0.1 mg/ml CHX in 7% ethanol was
prepared by filling up 88.81 μl of stock solution of 0.2% of
CHX digluconate in 7% ethanol to 1000 μl with matrix solu-
tion. This solution was further diluted twofold with matrix
solution to 1.9×10−7 mg/ml. Five replicates of 0.5 μl each
were taken from each aliquot and spotted onto the MALDI
target plate.
Recovery rate
Five working samples of CHX were prepared from the 0.2%
and 0.12% CHX rinsing solutions, 0.2% CHX spray and
0.12% CHX toothpastes. These samples with CHX concen-
trations of 0.28 μg/ml, 0.17 μg/ml, 0.28 μg/ml, 0.17 μg/ml,
and 0.17 μg/ml were obtained by diluting the original CHX
products with CHCA matrix solution. Five replicate samples
of 0.5 μl of each sample were spotted onto the MALDI target
plate for measurement.
MALDI-TOF mass spectrometry
MALDI-TOF analyses were performed on a Sciex
(Darmstadt, Germany) 4800 TOF/TOF mass spectrometer in
positive ion reflector mode over a range of m/z 370–600. The
Fig. 1 Palatal acrylic splint with mounted specimens to form the dental
pellicle samples
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system uses a pulsed 200-Hz solid-state Nd:YAG laser with a
wavelength of 355 nm. Laser energy was set to 2300 units for
standards and samples. Source 1 voltage was set to 20 kVwith
a grid voltage of 16 kV. The reflector detector voltage was set
to 2.19 kV. CHX standard (protonated monoisotopic mass
[Mi+H
+]+ at m/z 505.21, monoisotopic decay product [Mi+
H+-NH3]
+ at m/z 488.21 and the monoisotopic CHCA matrix
dimer [2Mi+H]
+ at m/z 379.09 were used for internal mass
calibration with a delay time of 600 ns. One average mass
spectrum was obtained from 20 sub-spectra per spot using
25 accepted laser shots each. Mass tolerance was set to ± 0.1
u with maximum outlier of 50 ppm. Accepted calibration set-
tings were used to measure sample spectra with a minimum
signal to noise range of 20 and resolution (FWHM) >8000.
The measured monoisotopic peaks were extracted into
Microsoft Excel worksheets. Their absolute intensities (ai)
were normalized by calculating the ratio of Iabs,ai and sum of
absolute intensities of all compounds in the investigated m/z
range according to Irel,ai= ai /Σ (a). This resulted in relative
intensities for the monoisotopic m/z 505.21 (=Irel 505,ai) of
CHX. For each sample, 5 replicate measurements were per-
formed using different sample spots and their relative intensi-
ties were averaged, resulting in a list of averaged monoisoto-
pic mass intensities Irel 505,ai for CHX. The averaged relative
intensities were used for calculating CHX concentrations
through the calibration curve.
Statistical analysis
All CHX values were expressed as mean ± standard
deviation and are presented in Tables 1, 2 and 3. The
data were analysed with GraphPad Prism 8 (GraphPad
Software, San Diego, CA, USA) using two-way repeat-
ed-measures analysis of variance (ANOVA) as two fac-
tors were changing during the experiment: sampling
time and CHX regimen. Multiple comparisons were
conducted with the Tukey test to reveal any significant
differences in the oral CHX retention between the dif-
ferent CHX regimens. Additionally, two-way ANOVA
was used to compare the retention of CHX in saliva
and in the buccal mucosa pellicle. In this case, the
two factors were the sampling time and the oral loca-
tion. Again, multiple comparisons were conducted with
the Tukey test to uncover potential significant differ-
ences in oral CHX retention between the different oral
locations. Kruskal-Wallis test followed by Dunn’s mul-
tiple comparison test was performed to investigate the
inter-individual variation in CHX retention after each
CHX regimen at different oral sites. For all compari-
sons, statistical significance was defined as p < 0.05.
It is important to note that repeated-measures ANOVA
test is quite sensitive to violations of the assumption of
sphericity or circularity. This violation could happen
when the repeated measurements are made too close to-
gether so that random factors that cause a particular value
to be high (or low) do not wash away or dissipate before
the next measurement. To avoid violating the assumption
of sphericity in the present study, an important washout
period of 10 days was applied to eliminate any rest of
CHX in the oral cavity from a treatment regimen which
can affect the retention values of the next treatment regi-
men. Additionally, the order of treatments was random
and each subject followed a different sequence of CHX
treatment regimens in his experimental trial.
Table 1 Mean (±SD) concentrations (μg/ml) of chlorhexidine (CHX) in the buccal mucosal pellicle over 12 h after application of different CHX
regimens
Chlorhexidine in the buccal mucosal pellicle (μg/ml)
Time
(h)
0.2% CHX - 60 s
rinse§
0.2% CHX - 30 s
rinse§
0.12% CHX - 60 s
rinse§










2 284 ± 65.1 262.3 ± 78 232.9 ± 9.2 231.7 ± 25.7 156 ± 39.5 1.8 ± 1.9 2.7 ± 2.3
4 172 ± 51.4 133 ± 42.3 127 ± 64.5 124.7 ± 63.6 46.3 ± 22.2 0.9 ± 0.8 0.3 ± 0.2
6 36.2 ± 23.3 24.7 ± 15.9 19.9 ± 13.1 20.7 ± 13.1 13.8 ± 20.3 - -
8 33.9 ± 18.8 11.6 ± 9.1 9.7 ± 5.1 7.5 ± 6.3 3.7 ± 2.4 - -
10 20.9 ± 16.3 7.2 ± 7.3 3.6 ± 3.3 4.6 ± 2.8 2.2 ± 1.9 - -
12 7.3 ± 5.2 2.1 ± 1.8 1.6 ± 3.3 1.3 ± 1.8 0.4 ± 0.4 - -
- chlorhexidine less than the limit of quantification
§ The differences in CHX retention between the rinsing regimens were not statistically significant (p > 0.05), except between 0.2% CHX rinsing for 60 s
and 0.12% CHX rinsing for 60 s (p = 0.015), as well as between 0.2% CHX rinsing for 60 s and 0.12% CHX rinsing for 30 s (p = 0.005)
†The differences in CHX retention between spray application and all other CHX rinsing regimens were statistically significant (p < 0.05)
The differences in CHX retention between toothpaste application and all other CHX regimens were statistically significant (p < 0.05)
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Results
Chlorhexidine calibration curve and recovery rate
Mass accuracies for the [Mi+H
+]+ m/z 505.21 measurements
were 25 ppm on average based on absolute m/z differences.
The calibration curves were linear from 1.5×10−3 to 0.39
μg/ml of CHX free base with a regression correlation coeffi-
cient of R2 = 0.9972 (Fig. 2).
The lowest concentration of the calibration curve was set as
the limit of quantification for CHX. Detection saturation was
observed for concentrations >0.39 μg/ml; concentrations
<1.5×10−3 μg/ml gave S/N ratios of 20 or less and prevented
CHX quantification. After determining CHX concentration in
the matrix sample mixtures, the dilution factor was applied for
calculating the CHX concentrations in the original oral
samples.
Additionally, the recovery was assessed by comparing the
obtained free CHX base content from the MALDI-TOF anal-
yses to the original sample concentrations of different CHX
regimens. The recovery rates of CHX in the present study
were between 95.03 and 98.86%.
Oral concentrations of chlorhexidine after application
of different regimens
The oral CHX concentrations at different sites continuously
decreased after application of different CHX regimens
Table 2 Mean (±SD) concentrations (μg/ml) of chlorhexidine (CHX) in the saliva over 12 h after application of different chlorhexidine regimens
Chlorhexidine in saliva (μg/ml)
Time
(h)
0.2% CHX - 60 s
rinse§
0.2% CHX - 30 s
rinse§
0.12% CHX - 60 s
rinse§










2 17.3 ± 10.7 25.7 ± 17.7 17.2 ± 6.8 11.4 ± 5.5 7.5 ± 5.6 0.1 ± 0.1 0.1 ± 0.1
4 10.7 ± 6.8 6.8 ± 4.7 8.9 ± 8.5 5.6 ± 3.9 3.3 ± 3.9 - -
6 4.6 ± 4.2 1.9 ± 1.6 3.4 ± 3.9 0.6 ± 0.3 0.6 ± 0.5 - -
8 2.3 ± 2.8 1.3 ± 1.2 1.4 ± 1.5 0.47 ± 0.3 0.4 ± 0.3 - -
10 1.4 ± 1.2 0.5 ± 0.6 0.4 ± 0.2 0.07 ± 0.03 0.1 ± 0.2 - -
12 0.5 ± 0.6 0.2 ± 0.1 0.2 ± 0.2 0.02 ± 0.03 - - -
- chlorhexidine less than the limit of quantification
§ The differences in CHX retention between the rinsing regimens were not statistically significant (p > 0.05)
†The differences in CHX retention between spray application and all other CHX rinsing regimens were not statistically significant (p > 0.05), except with
0.2% CHX rinsing for 60 s (p = 0.03)
The differences in CHX retention between toothpaste application and all other CHX regimens were statistically significant (p < 0.05)
Table 3 Mean (±SD) retention (μg/cm2) of chlorhexidine (CHX) in the dental pellicle over 12 h after application of different chlorhexidine regimens
Chlorhexidine in the dental pellicle (μg/cm2)
Time
(h)
0.2% CHX - 60 s
rinse§
0.2% CHX - 30 s
rinse§
0.12% CHX - 60 s
rinse§










2 0.33 ± 0.15 0.25 ± 0.09 0.32 ± 0.25 0.26 ± 0.15 0.15 ± 0.11 0.02 ± 0.02 0.01 ± 0.01
4 0.28 ± 0.09 0.18 ± 0.08 0.22 ± 0.17 0.18 ± 0.11 0.07 ± 0.04 0.01 ± 0.01 0.01 ± 0.01
6 0.21 ± 0.15 0.13 ± 0.06 0.09 ± 0.03 0.09 ± 0.08 0.05 ± 0.04 - -
8 0.12 ± 0.06 0.10 ± 0.04 0.05 ± 0.04 0.05 ± 0.03 0.04 ± 0.04 - -
10 0.06 ± 0.02 0.05 ± 0.04 0.03 ± 0.02 0.04 ± 0.03 0.02 ± 0.02 - -
12 0.06 ± 0.01 0.04 ± 0.03 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.02 - -
- chlorhexidine less than the limit of quantification
§ The differences in CHX retention between the rinsing regimens were not statistically significant (p > 0.05)
†The differences in CHX retention between spray application and all other CHX rinsing regimens were not statistically significant (p > 0.05), except with
0.2% CHX rinsing for 60 s (p = 0.005)
The differences in CHX retention between toothpaste application and all other CHX regimens were statistically significant (p < 0.05)
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(Figs. 3, 4 and 5). The highest decline rates of CHX concen-
tration in the oral cavity occurred during the first 6 h after
application followed by a time period of at least 12 h with
concentrations levels in the microgrammes per millilitre range
(Tables 1 and 2).
After application of the different CHX regimens, the reten-
tion rates of CHX in the buccal mucosa pellicle were always
higher compared to the retention in saliva (Tables 1 and 2).
After mouth rinsing, there were relatively higher retentions
in saliva, mucosal pellicle and dental pellicle when the mouth
rinse was performed either at a higher concentration of CHX
or at longer rinsing time. The CHX retention in the buccal
mucosa pellicle after the application of 0.2% CHX for 60 s
regimen was significantly more than the retention after using
0.12% CHX for 60 s regimen or 0.12% CHX for 30 s regimen
(p = 0.015, p = 0.005; respectively). However, the differences
between the rinsing protocols in the saliva and the dental pel-
licle were not statistically significant (p > 0.05) (Tables 2 and
3).
Considerable retention was detected after CHX spray
application. This retention lasted in the oral cavity for at
least 12 h (Table 1). Furthermore, there were no signif-
icant differences regarding the CHX retention between
the spray application and the rinsing regimens in saliva
and dental pellicle except with 0.2% CHX rinsing for
60 s (p = 0.03, p = 0.005; respectively). However, in
the buccal mucosa pellicle, the differences between the
spray application and the four rinsing regimens were
statistically significant.
In general, the retention of CHX changed as the dosage
of the CHX in different regimens changed. When the dosage
of the drug increased from 1.2 mg in the toothpaste to
3.28 mg in spray to 20 mg in the mouth rinse, the CHX
concentrations in the mucosal pellicle also increased from
2.74 to 156.08 μg/ml and finally to 284.12 μg/ml, 2 h after
application (Table 1). Similarly, as shown in Table 3, there
was significantly lower adsorption of CHX on the dental
pellicle when the toothpaste was used (0.01–0.03 μg/cm2)
compared with the retention obtained when the different
rinsing protocols were tested (0.25–0.6 μg/cm2) at 2-h time
point.
Fig. 2 Calibration curve of chlorhexidine (CHX)-concentrations versus
their relative intensity values. The linear range extends from 1.5×10−3 to
0.39 μg/ml. The linear equation and the quadratic correlation coefficients
are given for this range
Fig. 3 The mean concentrations (μg/ml) of chlorhexidine (CHX) in the
buccal mucosal pellicle over 12 h after application of different chlorhex-
idine regimens
Fig. 4 The mean concentrations (μg/ml) of chlorhexidine (CHX) in sali-
va over 12 h after application of different CHX regimens
Fig. 5 Themean retention (μg/cm2) of chlorhexidine (CHX) in the dental
pellicle over 12 h after application of different CHX regimens
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Lastly, no significant inter-individual differences were de-
tected after the statistical comparisons between the volunteers
regarding the CHX retention after each investigated regimen
in each oral location.
Discussion
This oral pharmacokinetic study investigated CHX retention
in different oral sites regarding different variables that may
affect this retention in the oral cavity, such as variations of
the rinsing time, drug concentration and delivery system.
MALDI-TOF was used for quantitative analysis of CHX,
as the alternatives HPLC and SPME techniques are time-
consuming and labour-intensive, despite their selectivity, sen-
sitivity and accuracy [28]. The characteristic isotope patterns
of the two chlorine isotopes (35Cl/37Cl) yielded three distinc-
tive ions (100% [35Cl35Cl]; 60% [35Cl37Cl+37Cl35Cl]; 9%
[37Cl37Cl]). Together with the accurate m/z determination,
the chlorine isotope patterns allowed unequivocal identifica-
tion of CHX in the measured mass spectra, as interfering en-
dogenous physiological components do not contain chlorine.
Neither salivary components, intakes of food and beverages
nor MALDI matrix signals interfered with the CHX isotope
patterns. The low quantification limit of 1.5×10−3 μg/ml and
the extended linear dynamic range both readily demonstrated
the fit-for-purpose of MALDI-TOF for quantifying CHX at
very low concentrations, combined with high recovery rates of
CHX (95–98%). These analytical figures of merit were com-
parable to previous studies using HPLC techniques, which
exhibited recovery rates between 93.2 [23] and 97.8% [26],
showing consistency throughout different studies and
techniques.
During the analysis of samples from the buccal mucosa
pellicle, dental pellicle and saliva, the CHX concentrations
varied at different oral locations in and between each subject.
Several previous studies showed the same inter-individual
variation after CHX application [15, 18, 24–26]. It appears
that these individual differences depended on individual oral
environment and food habits during the experiment. For ex-
ample, consuming acidic foods and drinks can lower the pH
within the oral cavity leading to reduced CHX retention [26,
33]. However, the inter-individual variations in the present
study were not statistically significant. Also, we investigated
the intra-individual variation in a previous retention study
[18], where experimental trials were replicated on three con-
secutive weeks. The intra-individual differences of CHX re-
tention were not statistically significant in the aforementioned
study.
The concentrations of CHX in the buccal mucosa pellicle
remained higher than 100 μg/ml for 4 h and then decreased
over time, mostly because of the main food meal intake. The
current results showed the CHX retention in the buccal
mucosa pellicle to be more than ten times higher than the
CHX retention in the saliva at all-time points. This might be
explained by the high affinity of CHX to the oral mucosa.
Such an affinity was noticed in a previous in vitro study,
which suggested that the presence of proteins in pellicles
and buccal epithelial cell membranes promote the adsorption
of CHX [26]. Similar results were also obtained in a previous
in situ study by analysing samples from different oral sites
including the mucosal pellicle and saliva [18], where CHX
retention in the mucosal pellicle was significantly higher than
in the saliva. However, the sampling techniques in both stud-
ies differed. In the previous study, samples were taken using
micro-brushes, whereas in the present study 2 μl samples were
taken from the buccal mucosal pellicle and the saliva.
The concentrations of salivary CHX remained at
microgrammes per millilitre levels up to 8 h after mouth rins-
ing. These results are in good agreement with previous studies
of salivary CHX retention [18, 25–27].
Raising the CHX concentration or prolonging the rinsing
time lead to a slight increase in CHX retention in the mucosal
pellicle, saliva and dental pellicle. The results of the present
study suggest that the maximum level of CHX retention is
achieved when the 0.2% CHX rinsing regimen is used for
60 s. Such retention results are in line with the conclusions
of a systemic review [34], where the authors found that there
was a small but significant difference in favour of the 0.2%
CHX concentration with regards to biofilm inhibition effects.
It was also reported in previously published studies that there
was higher retention by rising the CHX concentration from
0.1 to 1 mg/ml [26]. Bonesvoll and co-workers raised CHX
retention by raising the concentration or prolonging the rins-
ing time [33]. However, the authors noted that there was a
slight deviation towards less retention at the highest concen-
tration tested. Such a retention saturation could be due to the
limited binding capacity for CHX in the oral surfaces, which
would explain why there was only a small difference in the
retention values between 0.2 and 0.12% in this study.
Additionally, this finding indicates that increasing the concen-
trations of CHX for more than 0.2% or rinsing with more than
10 ml (more than 20 mg CHX dose) will not necessarily in-
duce significantly higher CHX retention and more persistent
bacteriostatic activity because of the binding capacity for
CHX in the oral cavity.
Attempts to overcome the side effects of prolonged CHX
use have resulted in the development of different CHX regi-
mens with various delivery systems and vehicles. These CHX
regimens employ smaller quantities of CHX and deliver the
drug to specific sites in the oral cavity. The CHX spray is one
of these regimens, which offers a simple and rapid method to
use very small doses of CHX of approximately one-seventh of
the dose from a rinse. The CHX spray offers an effective
plaque-inhibiting activity [10, 35]. The spray approach is par-
ticularly useful for elderly people and physically and mentally
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handicapped groups [9, 11, 36, 37]. This approach also allows
focusing on treatments of specific regions such as periodontal
or implant surgical sites [38, 39]. The results of the present in
situ study are in line with the conclusions obtained from the
aforementioned clinical studies. It was shown in the current
study that a considerable CHX retention is found after the
spray application, which might provide adjunctive benefits
to oral hygiene and gingival health with minimal side effects.
Adding CHX in dentifrice formulations to get both benefi-
cial approaches, mechanical and chemical cleaning is thought
to be helpful for patients with periodontal disease. However,
some components in the toothpaste gel are sometimes anionic
substances such as sodium lauryl sulphate (SLS). These sub-
stances could interfere with the biochemical pathway
(bioavailability) of the CHX by forming salts of low solubility
and low antibacterial activity [40]. Therefore, two different
kinds of CHX toothpaste were tested in this study, one with
SLS (Paroex) and another without it (Curasept), to determine
the retention of CHX in the oral cavity and the effect of SLS
on such retention.
The results of the present study showed no significant dif-
ference between toothpaste with or without SLS regarding
retention of CHX in the oral cavity. Furthermore, the CHX
from the toothpaste was retained in the oral cavity at low
concentrations and not to the same extent after a CHX mouth
rinse or even after a CHX spray application. The reason be-
hind this low retention could be due to the mechanical action
of the tooth brushing that can remove the newly attached CHX
particles at the dental pellicle. Additionally, rinsing the mouth
several times with water after tooth brushing might also wash
away the CHX particles from the oral cavity surfaces. In con-
trast, most of the retained CHX after mouth rinsing or spray
application is supposed to stay in the oral cavity after applica-
tion because patients should not further rinse their mouths
with water after using the mouthwash or spray. To overcome
the problem of washing away retained CHX after tooth
brushing, it was suggested in previous studies that CHX gel
could be delivered in trays or applied directly to teeth surfaces
with the finger [41]. This style of application, especially with
high CHX concentration, providedmore antibacterial efficien-
cy and caused a significant reduction of plaque scores and
gingival index [14]. Such an effectivity was comparable with
the mouth rinse in some studies [41, 42].
Another factor that can influence the retention of CHX after
toothpaste application is the dosage of the drug. It was shown
in a systematic review that the positive effects of CHX tooth-
paste were noticeable only when the concentration of CHX
was higher than 0.6% [13]. In this context, the 0.12% CHX
toothpaste used in this study delivered a low dosage of only
1.2 mg to the oral cavity, which is much lower than a 20 mg
CHX dose delivered by the rinsing. This small dosage of
1.2 mg CHX might explain why there was small retention
after application and almost no substantivity after 2 h. It is
also important to point out that CHX retention in the mucosal
pellicle after toothpaste application was recorded at 2 μg/ml at
the 2-h time point. This concentration may be sufficient as an
antibacterial agent for primary cariogenic bacteria such as
Streptococcus mutans, Actinomycetes and Lactobacilli [43].
However, it may be insufficient to destroy the subgingival
bacteria, which requires minimum inhibitory concentrations
(MICs) ranging from 8 to 250 μg/ml [44]. These MICs can
only be obtained after mouth rinsing or spray application.
Lastly, considering the main limitation of this study which
was the limited number of volunteers, further studies with a
higher number of subjects will be very helpful to confirm the
results of the present study and clarify more the effects of
different CHX delivery systems and treatment regimens on
the CHX retention in the oral cavity.
Conclusions
The results of the present study suggest that CHX concentra-
tion and the CHX delivery system play an essential role in
CHX retention in the oral cavity after application. The reten-
tion of CHX was much higher after mouth rinsing as com-
pared to toothpaste application. In the current study, the ap-
plication of 0.2% CHX for 60 s showed the best retention
values, which can provide a direct bactericidal and persistent
bacteriostatic activity in the oral cavity. This would be bene-
ficial when a significant reduction of oral bacteria is required,
such as for oral surgery preparations or for the treatment of
periodontal diseases.
Additionally, according to the high retention values record-
ed after the spray application, this type of CHX application
can be recommended, especially in special cases such as for
physically and mentally handicapped populations.
The current study also suggests that oral surfaces are
the main reservoirs of CHX. Subsequently, saliva, as a
constantly cleared and renewed substance in the oral
cavity, would acquire CHX at low concentrations from
other oral locations such as the mucosal surfaces and
dental pellicle. These low CHX concentrations in the
saliva would maintain a persistent bacteriostatic effect
against oral flora [16, 17].
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